Anexon's fail-safe BNP

Researchers at the Mayo Clinic and University of Minnesota have identified an alternatively spliced form of the hormone B-type natriuretic peptide that lacks the blood pressure-lowering effects that have curtailed the use of its regular form in heart failure patients.1 Later this year, Anexon Inc. plans to start Phase I testing for the splice variant ANX-042, one in the family of BNP splice variants from the Mayo Clinic that the company has exclusively licensed.

Natriuretic peptide precursor B (NPPB; BNP), also known as B-type natriuretic peptide, is a peptide hormone normally secreted by ventricular cardiomyocytes. The peptide helps clear salt and water from the body and also acts as a vasodilator to reduce blood pressure.2 During heart failure, the body tries to compensate

Read the full 1221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers